Anzeige
Mehr »
Login
Samstag, 18.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QAME | ISIN: US92556V1061 | Ticker-Symbol: VIA
Tradegate
17.01.25
20:12 Uhr
11,030 Euro
+0,035
+0,32 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
S&P 500
1-Jahres-Chart
VIATRIS INC Chart 1 Jahr
5-Tage-Chart
VIATRIS INC 5-Tage-Chart
RealtimeGeldBriefZeit
11,00011,04017.01.
10,97011,01517.01.
ACCESS Newswire
511 Leser
Artikel bewerten:
(2)

Viatris Named to TIME's World's Most Sustainable Companies 2024 List

Finanznachrichten News

PITTSBURGH, PA / ACCESSWIRE / June 25, 2024 / Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that it has been named to the inaugural edition of TIME's World's Most Sustainable Companies 2024. This recognition is presented by TIME and Statista Inc., the world-leading statistics portal and industry ranking provider.

The World's Most Sustainable Companies 2024 list recognizes leading companies in corporate social responsibility from over 30 countries. Companies were evaluated in more than 20 key performance indicators related to sustainability management and disclosure, such as greenhouse gas emissions, commitment to goals and initiatives and compliance with international reporting standards. Out of over 5,000 of the world's largest and most influential companies assessed, the top 500 were awarded based on revenue, market capitalization, and public prominence.

"Being included on TIME's World's Most Sustainable Companies 2024 list is acknowledgement of our colleagues' continuous work to advance more sustainable operations and responsible practices that enable Viatris to supply high-quality medicines to approximately 1 billion patients around the world annually," said Lina Andersson, Head of Global Sustainability, Viatris. We have worked diligently and will continue to do so, to be considered a trusted partner as we work to help close gaps to access to care, build more resilient healthcare systems, and uphold a reliable global supply of medicines."

Viatris is a signatory to the U.N. Global Compact based on our belief that companies can be relevant partners in the collective efforts required to address many of these persistent challenges. As a global healthcare company with an exceptionally broad and diverse portfolio, global reach and a mission to empower people worldwide to live healthier at every stage of life, Viatris' most significant contribution is building sustainable access to medicine at scale - which is core to the Company's business and is the foundation of its operating and business model.

Being named to TIME's World's Most Sustainable Companies 2024 list follows inclusion on USA TODAY's list of America's Climate Leaders this past May.

Other accolades for Viatris include inclusion on 3BL's 100 Best Corporate Citizens of 2023 Ranking, Newsweek's America's Greenest Companies 2024, TIME's World's Best Companies 2023 list and Forbes' list of World's Best Employers 2023. The Company has also been included on Forbes' list of World's Best Employers 2022 and 2021, and has received Great Place to Work® certifications and Top Employers certifications in multiple countries, among others.

To learn more about Viatris' efforts and overall impact, visit Viatris' 2023 Sustainability Report.

About Viatris
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X (formerly Twitter).

SOURCE Viatris Inc.

For further information: MEDIA: +1.724.514.1968, Communications@viatris.com; Jennifer Mauer, Jennifer.Mauer@viatris.com; Matt Klein, Matthew.Klein@viatris.com; INVESTORS: Bill Szablewski, +1.412.707.2866, InvestorRelations@viatris.com, William.Szablewski@viatris.com

View additional multimedia and more ESG storytelling from Viatris on 3blmedia.com.

Contact Info:
Spokesperson: Viatris
Website: https://www.3blmedia.com/profiles/viatris
Email: info@3blmedia.com

SOURCE: Viatris



View the original press release on accesswire.com

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.